Towa Pharmaceutical Co., Ltd.
Toa Pharmaceutical Co., Ltd. Q1 2027 Financial Summary (Consolidated) [Japanese GAAP]
For the first quarter of the fiscal year ending March 2027, consolidated net sales were 71,380 million yen, up 9.6% year over year; operating income was 6,519 million yen, up 25.2% YoY; ordinary income was 7,941 million yen (derivative valuation gains of 1,424 million yen included); net income attributable to owners of the parent for the quarter was 5,531 million yen, marking a substantial increase. The full-year guidance remains unchanged. Both domestic and overseas segments posted higher sales, with overseas growth driven by expansion in Europe. Equity ratio 38.0%; cash and deposits, etc. 41,724 million yen.
Key Figures
- Sales: 71,380百万円（前年同期比9.6%増）
- Operating profit: 6,519百万円（同25.2%増）
- Net income attributable to owners of the parent for the quarter: 5,531百万円（同120.1%増）
AI要約
Outlook and Financial Position
Total assets stood at 480,709 million yen, with shareholders’ equity ratio at 38.0%, indicating stability. Inventory increases and higher accounts receivable contributed to solid cash flow. A supplemental earnings materials and an earnings briefing are planned, with no revision to earnings forecasts at this time. As measures to stabilize supply in the pharmaceutical industry continue, strengthening production and supply frameworks domestically and internationally has contributed to results.
Toa Pharmaceutical Co., Ltd.
Company overview · Stock price · Financial data · All IR
